2008
DOI: 10.1038/cdd.2008.6
|View full text |Cite
|
Sign up to set email alerts
|

The mechanism of peptide-binding specificity of IAP BIR domains

Abstract: We describe the peptide-binding specificity of the baculoviral IAP repeat (BIR) domains of the human inhibitor of apoptosis (IAP) proteins, X-linked IAP, cellular IAP1 and neuronal apoptosis inhibitory protein (NAIP). Synthetic peptide libraries were used to profile each domain, and we distinguish two types of binding specificity, which we refer to as type II and type III BIR domains. Both types have a dominant selectivity for Ala in the first position of the four N-terminal residues of the peptide ligands, wh… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
39
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 41 publications
(43 citation statements)
references
References 41 publications
4
39
0
Order By: Relevance
“…Several of these are SMAC mimetics developed to target the BIR3 and/or the BIR2 domains of XIAP, c-IAP1, and c-IAP2, and have shown promising preclinical results even in melanoma (39, 40). Although Apollon binds SMAC (14) and its only BIR domain belongs to the type II class, as the BIR2 domain of XIAP, c-IAP1, and c-IAP2 (41), it is not clear whether available SMAC mimetics also inhibit Apollon. However, other recently developed IAP antagonists are antisense oligonucleotides targeting XIAP or survivin (see ref.…”
Section: Discussionmentioning
confidence: 99%
“…Several of these are SMAC mimetics developed to target the BIR3 and/or the BIR2 domains of XIAP, c-IAP1, and c-IAP2, and have shown promising preclinical results even in melanoma (39, 40). Although Apollon binds SMAC (14) and its only BIR domain belongs to the type II class, as the BIR2 domain of XIAP, c-IAP1, and c-IAP2 (41), it is not clear whether available SMAC mimetics also inhibit Apollon. However, other recently developed IAP antagonists are antisense oligonucleotides targeting XIAP or survivin (see ref.…”
Section: Discussionmentioning
confidence: 99%
“…Indeed, cIAPs, XIAP and ML-IAP can bind caspase-3, -7, and -9 via the BIRs10,11,45,46 and can induce their ubiquitination or neddylation via the RING domain 19,2224. The influence of the ubiquitination is still not very well established, triggering degradative or nondegradative consequences,2224 while the neddylation of caspase-7, by XIAP, inhibits its activity 19.…”
Section: Role Of Iaps In Cancermentioning
confidence: 99%
“…5,6 In the presence of apoptotic stimuli, IAP antagonists are activated and competitively bind to IAPs through an IAP-binding motif (IBM) leading to IAP ubiquitination and consequent degradation of both IAPs and IBM-domain proteins. 7,8 In mammals, both IAPs and IBM-domain proteins of the Smac/Diablo and Omi/HtrA2 families are also present, but they are ubiquitously expressed. In contrast, the IBM-domain proteins Reaper, Hid and Grim (RHG) in Drosophila are transcriptionally activated in response to many different hormonal, stress and developmental signals.…”
mentioning
confidence: 99%